Editorial Board — Medscape Diabetes & Endocrinology

Board Members

 

Board Member Details

Aaron R. Chidakel, MD
Cyrus V. Desouza, MBBS

Assistant Professor, Department of Medicine, New York University, New York City, New York

Aaron R. Chidakel, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or member of a speakers bureau for: AbbVie, sanofi-aventis, Boehringer Ingelheim Pharmaceuticals, Inc.

Cyrus V. Desouza, MBBS
Cyrus V. Desouza, MBBS

Professor; Chief, University of Nebraska Medical Center; Chief, Division of Endocrinology; Director, Diabetes and Obesity Program, The Nebraska MedicalCenter/VA Nebraska-Western Iowa Healthcare System, Omaha, Nebraska

Cyrus V. Desouza, MBBS, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Novo Nordisk

Vivian Fonseca, MD
Vivian Fonseca, MD

Professor of Medicine, Tulane University, New Orleans, Louisiana

Vivian Fonseca, MD, has disclosed the following relevant financial relationships:
Received research support (to Tulane): Grants from Novo Nordisk; Asahi; Eli Lilly and Company; Abbott Laboratories; Endo Barrier; Gilead Sciences
Honoraria for Consulting and Lectures: Takeda Pharmaceuticals North America, Inc; Novo Nordisk; sanofi-aventis; Eli Lilly and Company; Pamlabs; AstraZeneca; Abbott Laboratories; Amgen; Boehringer
Ingelheim Pharmaceuticals, Inc; Ortho-McNeil-Janssen Pharmaceuticals, Inc

Per-Henrik Groop, MD, DMSc
Per-Henrik Groop, MD, DMSc

Professor of Nephrology, Chair, Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland

Per-Henrik Groop, MD, DMSc, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Cebix Incorporated; Eli Lilly and Company; Novartis Pharmaceuticals Corporation
Serve(d) as a speaker or member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Genzyme Corporation; Merck Sharp & Dohme Corp; Novartis Pharmaceuticals Corporation; Novo Nordisk
Received research grant from: Eli Lilly and Company; Roche

Simon R. Heller, MB BChir, DM, FRCP
Simon R. Heller, MB BChir, DM, FRCP

Professor of Clinical Diabetes, Department of Oncology and Metabolism, University of Sheffield School of Medicine; Honorary Consultant Physician, Department of Diabetes and Endocrinology, Sheffield Teaching Hospitals Foundation Trust, Sheffield, South Yorkshire, United Kingdom

Simon R. Heller, MB BChir, DM, FRCP, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.
Serve(d) as a speaker or member of a speakers bureau for: Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.; Merck Sharp & Dohme Corp.; AstraZeneca Pharmaceuticals LP
Received research grant from: Medtronic UK Ltd

Scott Kahan, MD, MPH

Faculty, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University; Medical Director, Strategies to Overcome and Prevent (STOP) Obesity Alliance, George Washington University, Washington, DC

Scott Kahan, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Takeda; Novo Nordisk; Vivus
Serve(d) on the board of directors for: American Board of Obesity Medicine
Received book royalties from: Johns Hopkins University Press

Anne L. Peters, MD
Anne L. Peters, MD, CDE

Professor, Endocrinology, Keck School of Medicine, University of Southern California, Los Angeles, California; Director, University of Southern California Clinical Diabetes Programs, University of Southern California Westside Center for Diabetes, Beverly Hills, California

Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbott Diabetes Care; Becton, Dickinson and Company; Bigfoot Biomedical; Biodel; Boehringer Ingelheim Pharmaceuticals, Inc.; CVS/Caremark; Eli Lilly and Company; Bristol-Myers Squibb Company; AstraZeneca Pharmaceuticals LP; Intarcia; Merck & Co., Inc.; Janssen Pharmaceuticals, Inc; Lexicon; Novo Nordisk; Omada Health; OptumRx; Thermalin
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for:
Abbott Diabetes Care; Becton, Dickinson and Company; Bigfoot Biomedical; Biodel; Boehringer Ingelheim Pharmaceuticals, Inc.; CVS/Caremark; Eli Lilly and Company; Bristol-Myers Squibb Company; AstraZeneca Pharmaceuticals LP; Intarcia; Merck & Co., Inc.; Janssen Pharmaceuticals, Inc; Lexicon; Novo Nordisk; Omada Health; OptumRx; Thermalin
Serve(d) as a speaker or a member of a speakers bureau for: Janssen Pharmaceuticals, Inc; Eli Lilly and Company (ended June 1, 2015)
Received a research grant from: Janssen Pharmaceuticals, Inc; Medtronic, Inc.

Arya M Sharma, MD, PhD, DSc (h.c.), FRCPC
Arya M Sharma, MD, PhD, DSc (h.c.), FRCPC

Professor of Medicine, Chair of Obesity Research & Management, University of Alberta; Royal Alexandra Hospital, Weight Wise Clinic, Edmonton, Alberta

Arya M Sharma, MD, PhD, DSc (h.c.), FRCPC, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Novo Nordisk; Zalgen Labs; Vivus, Inc.; Takeda Pharmaceuticals North America, Inc.; Ethicon, Inc.
Serve(d) as a speaker or a member of a speakers bureau for: Novo Nordisk; Zalgen Labs; Vivus, Inc.; Takeda Pharmaceuticals North America, Inc.; Ethicon, Inc.

Dace L. Trence, MD
Dace L. Trence, MD

Professor, Department of Medicine; Director, Diabetes Care Center, University of Washington, Seattle

Dace Trence, MD, has disclosed no relevant financial relationships.